Follow
Françoise Descotes
Françoise Descotes
Verified email at chu-lyon.fr
Title
Cited by
Cited by
Year
Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts
M David, E Wannecq, F Descotes, S Jansen, B Deux, J Ribeiro, CM Serre, ...
PloS one 5 (3), e9741, 2010
1392010
miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis–associated genes
M Croset, F Pantano, CWS Kan, E Bonnelye, F Descotes, ...
Cancer research 78 (18), 5259-5273, 2018
1192018
Validation of tumor‐associated macrophage ferritin light chain as a prognostic biomarker in node‐negative breast cancer tumors: A multicentric 2004 national PHRC study
P Jézéquel, L Campion, F Spyratos, D Loussouarn, M Campone, ...
International journal of cancer 131 (2), 426-437, 2012
992012
Dual Function of ERRα in Breast Cancer and Bone Metastasis Formation: Implication of VEGF and OsteoprotegerinERRα and Bone Metastasis
A Fradet, H Sorel, L Bouazza, D Goehrig, B Dépalle, A Bellahcene, ...
Cancer research 71 (17), 5728-5738, 2011
832011
S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study
A Chassevent, ML Jourdan, S Romain, F Descotes, M Colonna, ...
Clinical cancer research 7 (4), 909-917, 2001
822001
Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine
F Descotes, N Kara, M Decaussin-Petrucci, E Piaton, F Geiguer, ...
British journal of cancer 117 (4), 583-587, 2017
742017
Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and …
M David, J Ribeiro, F Descotes, CM Serre, M Barbier, M Murone, ...
International journal of oncology 40 (4), 1133-1141, 2012
622012
High expression of gabarapl1 is associated with a better outcome for patients with lymph node-positive breast cancer
A Berthier, S Seguin, AJ Sasco, JY Bobin, G De Laroche, J Datchary, ...
British journal of cancer 102 (6), 1024-1031, 2010
542010
Human breast cancer: correlation study between HER-2/neu amplification and prognostic factors in an unselected population.
F Descotes, JJ Pavy, GL Adessi
Anticancer research 13 (1), 119-124, 1993
471993
Prognostic of DNA‐synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1–T2, N0–N1, M0 breast cancers: A retrospective multicenter study
S Romain, F Spyratos, F Descotes, A Daver, B Rostaing‐Puissant, ...
International journal of cancer 87 (6), 860-868, 2000
452000
Molecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy
M Decaussin‐Petrucci, F Descotes, L Depaepe, V Lapras, ML Denier, ...
Cytopathology 28 (6), 482-487, 2017
442017
Predictive factors of outcome in poorly differentiated thyroid carcinomas
C de la Fouchardière, M Decaussin-Petrucci, J Berthiller, F Descotes, ...
European Journal of Cancer 92, 40-47, 2018
422018
TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma
C Bournaud, F Descotes, M Decaussin-Petrucci, J Berthiller, ...
European Journal of Cancer 108, 41-49, 2019
382019
Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase …
F Descotes, B Riche, S Saez, G De Laroche, J Datchary, P Roy, J André, ...
Clinical breast cancer 8 (2), 168-177, 2008
382008
The co-occurrence of an ovarian Sertoli-Leydig cell tumor with a thyroid carcinoma is highly suggestive of a DICER1 syndrome
E Durieux, F Descotes, C Mauduit, M Decaussin, S Guyetant, ...
Virchows Archiv 468 (5), 631-636, 2016
332016
High expression of QSOX1 reduces tumorogenesis, and is associated with a better outcome for breast cancer patients
N Pernodet, F Hermetet, P Adami, A Vejux, F Descotes, C Borg, M Adams, ...
Breast Cancer Research 14 (5), 1-15, 2012
312012
Keeping data continuous when analyzing the prognostic impact of a tumor marker: an example with cathepsin D in breast cancer
N Bossard, F Descotes, AG Bremond, Y Bobin, P De Saint Hilaire, ...
Breast cancer research and treatment 82 (1), 47-59, 2003
302003
Identification of Heparin-Binding EGF-Like Growth Factor (HB-EGF) as a Biomarker for Lysophosphatidic Acid Receptor Type 1 (LPA1) Activation in Human Breast …
M David, D Sahay, F Mege, F Descotes, R Leblanc, J Ribeiro, P Clézardin, ...
PLoS One 9 (5), e97771, 2014
242014
Microarray gene expression profiling and analysis of bladder cancer supports the sub‐classification of T 1 tumours into T 1a and T 1b stages
F Descotes, P Dessen, PP Bringuier, M Decaussin, PM Martin, M Adams, ...
BJU international 113 (2), 333-342, 2014
222014
Somatic DICER1 gene mutation in sporadic intraocular medulloepithelioma without pleuropulmonary blastoma syndrome
E Durieux, F Descotes, AM Nguyen, JD Grange, ...
Human pathology 46 (5), 783-787, 2015
212015
The system can't perform the operation now. Try again later.
Articles 1–20